This is a summary of the European public assessment report (EPAR) for Azarga. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Azarga.
Therapeutic Indication
Decrease of intraocular pressure (IOP) in adult patients with open angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction.
Therapeutic Area (MeSH)
ATC Code
S01ED51
ATC Item
N/A
Pharmacotherapeutic Group
Ophthalmologicals
Active Substance (Summary)
INN / Common Names
EMA Name
Azarga
Medicine Name
Azarga
Aliases
N/ANo risk management plan link.
